NEW YORK, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)ALZHEIMER'S DRUG DISCOVERY FOUNDATION, founded in 2004, is a mid-sized nonprofit in the Social Science sector that reported $37.7M in total revenue in fiscal year 2023. Revenue fell 85% from the prior year — a significant decline worth monitoring. Expenses of $61.9M exceeded revenue, resulting in a 64% operating deficit.
ACCELERATE THE DISCOVERY OF DRUGS TO PREVENT, TREAT AND CURE ALZHEIMER'S DISEASE AND RELATED DEMENTIAS.
THE ALZHEIMER'S DRUG DISCOVERY FOUNDATION IS DEDICATED TO RAPIDLY ACCELERATING THE DISCOVERY OF DRUGS TO PREVENT, TREAT AND CURE ALZHEIMER'S DISEASE AND RELATED DEMENTIAS. THE ADDF IS SOLELY FOCUSED...
THE ALZHEIMER'S DRUG DISCOVERY FOUNDATION IS DEDICATED TO RAPIDLY ACCELERATING THE DISCOVERY OF DRUGS TO PREVENT, TREAT AND CURE ALZHEIMER'S DISEASE AND RELATED DEMENTIAS. THE ADDF IS SOLELY FOCUSED ON FUNDING THE DEVELOPMENT OF DRUGS FOR ALZHEIMER'S, EMPLOYING A VENTURE PHILANTHROPY MODEL TO SUPPORT RESEARCH IN ACADEMIA AND THE BIOTECH INDUSTRY.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $37,742,020 | $254,027,105 | -0.9% |
| Expenses | $61,943,588 | $36,842,901 | +0.7% |
| Net Income | $-24,201,568 | $217,184,204 | -1.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| ALICE SHURE | GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| BEATRIZ ILLESCAS PUTZEYS-CLAUGUS | GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| BONNIE PFEIFER EVANS | GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| DAVID WEINREB | GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| GARY M LAUDER | GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| HOWARD FILLIT MD | FOUNDING EXEC. DIR. & CHIEF SCI. OFF. | 40.00 |
Officer
Director
|
$632,502 | $32,404 | $664,906 |
| LANNY EDELSOHN MD | GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| LAURENCE LEEDS JR | GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| LEONARD LAUDER | CO-CHAIRMAN /GOVERNOR | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| MELVIN GOODES | HONORARY GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| MIIA KIVIPELTO MD PHD | GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| NANCY CORZINE | GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| NANCY GOODES | GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| PAULA ZAHN | GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| RANDAL SANDLER | CO-VICE CHAIRMAN & SECRETARY | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| RICHARD MOHS PHD | GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| ROBERT BELFER | GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| ROBERTA DIAZ BRINTON PHD | GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| RONALD LAUDER | CO-CHAIRMAN /GOVERNOR | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| SANDRA DAY O'CONNOR | HONORARY CHAIRMAN | 1.00 |
Director
|
$0 | $0 | $0 |
| SHARON SAGER | GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| THOMAS MCWILLIAMS | CO-VICE CHAIRMAN & TREASUR | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| THOMAS SMITH JR | GOVERNOR | 1.00 |
Director
|
$0 | $0 | $0 |
| KAREN HARRIS | CFO AND HEAD OF MISSION | 40.00 |
Officer
|
$366,749 | $24,726 | $391,475 |
| MARK ROITHMAYR | CEO | 40.00 |
Officer
|
$619,606 | $39,387 | $658,993 |
| AARON BURSTEIN | HEAD OF SEARCH AND EVALUATION | 40.00 |
Highest
|
$301,736 | $48,360 | $350,096 |
| CHRISTOPHER CARLSON | DIRECTOR, SEARCH & EVALUATION | 40.00 |
Highest
|
$182,770 | $30,842 | $213,612 |
| JANE MCINTOSH | CHIEF EXTERNAL AFFAIRS | 40.00 |
Highest
|
$359,470 | $12,350 | $371,820 |
| LAKITA CAVIN | ATTORNEY, MISSION-RELATED INVESTMENTS | 40.00 |
Highest
|
$208,205 | $21,418 | $229,623 |
| LAURA NISENBAUM | EXECUTIVE DIRECTOR, DRUG DEV. | 40.00 |
Highest
|
$434,157 | $32,393 | $466,550 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $37,742,020 | $61,943,588 | $324,173,528 | $-24,201,568 |
| 2022 | $254,027,105 | $36,842,901 | $340,253,841 | $217,184,204 |
| 2021 | $53,037,104 | $37,126,176 | $116,420,075 | $15,910,928 |
| 2020 | $27,631,350 | $28,251,909 | $97,381,722 | $-620,559 |
| 2019 | $22,712,391 | $32,429,304 | $97,175,562 | $-9,716,913 |
| 2018 | $55,817,240 | $16,190,686 | $90,038,223 | $39,626,554 |
Compare ALZHEIMER'S DRUG DISCOVERY FOUNDATION with other nonprofits in New York and across the country.